After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out about its atopic dermatitis treatment Ebglyss. Ebglyss is a once-monthly ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Analysts expect the pill to be as ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

This was the stock's second consecutive day of losses.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments.

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, diabetes and migraine medicines. Patients will now be able to use ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of ...

The much-awaited weightloss and diabetes drug, Mounjaro from US-based Eli Lilly and Company will be available at local chemists in a few weeks, at an India-specific price. Globally Mounjaro, and ...